It has been documented that the oncometabolite (R)-2-hydroxyglutarate (2-HG) disrupts mitochondrial function via inhibition of cytochrome c oxidase, thereby increasing the efficacy of VEN in IDH-mutated AML (23, 24). Here, IDH2 is linked to acute myeloid leukemia.